- Home
- TVTX vs HROW Comparison
TVTX vs HROW Comparison
Compare TVTX & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVTX
- HROW
- Stock Information
- Founded
- TVTX 2008
- HROW 1998
- Country
- TVTX United States
- HROW United States
- Employees
- TVTX N/A
- HROW N/A
- Industry
- TVTX Biotechnology: Pharmaceutical Preparations
- HROW Biotechnology: Pharmaceutical Preparations
- Sector
- TVTX Health Care
- HROW Health Care
- Exchange
- TVTX Nasdaq
- HROW Nasdaq
- Market Cap
- TVTX 1.4B
- HROW 1.1B
- IPO Year
- TVTX N/A
- HROW N/A
- Fundamental
- Price
- TVTX $16.48
- HROW $34.93
- Analyst Decision
- TVTX Strong Buy
- HROW Strong Buy
- Analyst Count
- TVTX 16
- HROW 7
- Target Price
- TVTX $33.33
- HROW $61.83
- AVG Volume (30 Days)
- TVTX 1.6M
- HROW 378.2K
- Earning Date
- TVTX 07-31-2025
- HROW 08-06-2025
- Dividend Yield
- TVTX N/A
- HROW N/A
- EPS Growth
- TVTX N/A
- HROW N/A
- EPS
- TVTX N/A
- HROW N/A
- Revenue
- TVTX $273,533,000.00
- HROW $212,858,000.00
- Revenue This Year
- TVTX $73.84
- HROW $44.89
- Revenue Next Year
- TVTX $46.72
- HROW $38.22
- P/E Ratio
- TVTX N/A
- HROW N/A
- Revenue Growth
- TVTX 75.65
- HROW 53.49
- 52 Week Low
- TVTX $7.93
- HROW $20.85
- 52 Week High
- TVTX $25.29
- HROW $59.23
- Technical
- Relative Strength Index (RSI)
- TVTX 59.73
- HROW 70.24
- Support Level
- TVTX $14.44
- HROW $30.81
- Resistance Level
- TVTX $16.64
- HROW $33.27
- Average True Range (ATR)
- TVTX 0.61
- HROW 1.37
- MACD
- TVTX 0.31
- HROW 0.09
- Stochastic Oscillator
- TVTX 94.18
- HROW 88.78
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.